Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 01 Mar 2023
United States: According to a recent study published in Science Advances, the first small stretch elastic bandage heals.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.
Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’
After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.
FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years
Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children
1.
Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality
2.
Novel probes to label macrophages associated with cancer progression using a selective dye
3.
More nonsmokers are getting lung cancer: Oncologist explains why
4.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
5.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
1.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
2.
Uncovering the Role of Pap Smear in Oncology: A New Frontier in Cancer Detection
3.
A Closer Look at MCV Modules: Features, Functions, and Benefits
4.
Understanding Colon Cancer: Symptoms, Causes, and Treatment Options
5.
A New Hope: Exploring the Benefits of Exenteration for Cancer Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge